Payment overview · 2025
General Payments
$1,825.64
77 reported records · 21 companies
Healthcare provider profile · identity verified
Daniel Nader Niknam, DO
Allopathic & Osteopathic Physicians|Internal Medicine · INGLEWOOD, CA · NPI 1598262073
Verified facts
What the public records show
CMS Open Payments records show Daniel Nader Niknam, DO received $1,825.64 in general payments during 2025 across 77 reported records.
GlaxoSmithKline, LLC. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1220 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1220 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $533.26 | 29.2% | 25 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $241.56 | 13.2% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $173.54 | 9.5% | 7 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $80.38 | 4.4% | 6 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $78.66 | 4.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $77.67 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.92 | 3.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.44 | 3.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $56.85 | 3.1% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $55.18 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.97 | 2.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.59 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.60 | 2.3% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.17 | 2.3% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.67 | 2.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.77 | 1.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.53 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.20 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.62 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.56 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,783.14 | 76 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $298.22 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $284.16 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $214.48 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $173.54 | 7 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $80.38 | 6 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $78.66 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $77.67 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.92 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $59.44 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $57.07 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $55.18 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 18 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1220 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
450 | 78 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1220 | 154 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
450 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
168 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1220 | 154 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2160 | 410 |
| Amlodipine Besylate | Amlodipine Besylate | 1649 | 323 |
| Gabapentin | Gabapentin | 1280 | 240 |
| Eliquis | Apixaban | 1220 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 944 | 196 |
| Metformin Hcl | Metformin Hcl | 899 | 165 |
| Furosemide | Furosemide | 761 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 115 |
| Losartan Potassium | Losartan Potassium | 658 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 628 | 128 |
| Famotidine | Famotidine | 607 | 139 |
| Metoprolol Tartrate | Metoprolol Tartrate | 560 | 112 |
| Carvedilol | Carvedilol | 518 | 107 |
| Lisinopril | Lisinopril | 482 | 105 |
| Jardiance | Empagliflozin | 450 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 430 | 93 |
| Risperidone | Risperidone | 421 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 387 | 84 |
| Quetiapine Fumarate | Quetiapine Fumarate | 373 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 341 | 114 |
| Mirtazapine | Mirtazapine | 300 | 65 |
| Trazodone Hcl | Trazodone Hcl | 300 | 87 |
| Potassium Chloride | Potassium Chloride | 295 | 72 |
| Donepezil Hcl | Donepezil Hcl | 292 | 52 |
| Divalproex Sodium | Divalproex Sodium | 279 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 276 | 90 |
| Levetiracetam | Levetiracetam | 269 | 53 |
| Baclofen | Baclofen | 262 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 259 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 47 |
| Omeprazole | Omeprazole | 246 | 51 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 229 | 109 |
| Memantine Hcl | Memantine Hcl | 225 | 36 |
| Lactulose | Lactulose | 217 | 75 |
| Clonidine Hcl | Clonidine Hcl | 215 | 103 |
| Olanzapine | Olanzapine | 203 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 202 | 86 |
| Sertraline Hcl | Sertraline Hcl | 196 | 42 |
| Montelukast Sodium | Montelukast Sodium | 195 | 35 |
| Latanoprost | Latanoprost | 181 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 56 |
| Spironolactone | Spironolactone | 172 | 45 |
| Tramadol Hcl | Tramadol Hcl | 172 | 63 |
| Entresto | Sacubitril/Valsartan | 168 | 35 |
| Finasteride | Finasteride | 167 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 44 |
| Lidocaine | Lidocaine | 159 | 42 |
| Ibuprofen | Ibuprofen | 157 | 62 |
| Nifedipine Er | Nifedipine | 157 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 151 | 25 |
| Januvia | Sitagliptin Phosphate | 150 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 148 | 23 |
| Allopurinol | Allopurinol | 145 | 28 |
| Lorazepam | Lorazepam | 130 | 70 |
| Buspirone Hcl | Buspirone Hcl | 126 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 126 | 70 |
| Benztropine Mesylate | Benztropine Mesylate | 125 | 30 |
| Atenolol | Atenolol | 123 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 36 |
| Xarelto | Rivaroxaban | 121 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 31 |
| Simvastatin | Simvastatin | 116 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 18 |
| Midodrine Hcl | Midodrine Hcl | 108 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 104 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 34 |
| Glipizide | Glipizide | 91 | 19 |
| Sodium Chloride | 0.9 % Sodium Chloride | 91 | 44 |
| Santyl | Collagenase Clostridium Hist. | 89 | 39 |
| Benazepril Hcl | Benazepril Hcl | 88 | 17 |
| Humalog | Insulin Lispro | 87 | 27 |
| Clozapine | Clozapine | 86 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 81 | 21 |
| Propranolol Hcl | Propranolol Hcl | 81 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 26 |
| Aripiprazole | Aripiprazole | 75 | 22 |
| Humulin R | Insulin Regular, Human | 75 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 74 | 15 |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Meloxicam | Meloxicam | 71 | 23 |
| Ezetimibe | Ezetimibe | 69 | 20 |
| Prednisone | Prednisone | 68 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 49 |
| Megestrol Acetate | Megestrol Acetate | 66 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 65 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 45 |
| Digoxin | Digoxin | 63 | 16 |
| Valsartan | Valsartan | 60 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 33 |
| Azithromycin | Azithromycin | 58 | 49 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 46 |
| Mupirocin | Mupirocin | 57 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 55 | 18 |
| Sucralfate | Sucralfate | 54 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Olanzapine Odt | Olanzapine | 51 | suppressed |
| Rexulti | Brexpiprazole | 51 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 16 |
| Levofloxacin | Levofloxacin | 50 | 40 |
| Methocarbamol | Methocarbamol | 50 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Cephalexin | Cephalexin | 49 | 37 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 48 | 14 |
| Brilinta | Ticagrelor | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 23 |
| Nystatin | Nystatin | 46 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 15 |
| Kapspargo Sprinkle | Metoprolol Succinate | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 26 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 15 |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Insulin Lispro | Insulin Lispro | 40 | 17 |
| Methimazole | Methimazole | 40 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 39 | 18 |
| Calcium Acetate | Calcium Acetate | 39 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Naproxen | Naproxen | 39 | 12 |
| Novolog | Insulin Aspart | 39 | suppressed |
| Temazepam | Temazepam | 39 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 11 |
| Ozempic | Semaglutide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | 11 |
| Primidone | Primidone | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 14 |
| Ketoconazole | Ketoconazole | 35 | 25 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 23 |
| Ondansetron Odt | Ondansetron | 31 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 17 |
| Sevelamer Hcl | Sevelamer Hcl | 30 | suppressed |
| Ertapenem | Ertapenem Sodium | 29 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Daptomycin | Daptomycin | 28 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Novolin R | Insulin Regular, Human | 25 | 13 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Mesalamine | Mesalamine | 21 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Permethrin | Permethrin | 19 | 13 |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Glucagon Emergency Kit | Glucagon | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 16 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | 12 |
| Methazolamide | Methazolamide | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Brinzolamide | Brinzolamide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Ivermectin | Ivermectin | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine | Nifedipine | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,825.64 · 77 records | GlaxoSmithKline, LLC. | AFREZZA, AREXVY, Arikayce, COBENFY, DUPIXENT, ELIQUIS, ELYXYB - CELECOXIB, GVOKE HYPOPEN, Kerendia, LEQVIO, MOUNJARO, NUCALA, NURTEC ODT, OFEV, OPSUMIT, OPSYNVI, Ozempic, PAXLOVID, PURIFIED CORTROPHIN GEL, REXULTI, SHINGRIX, SMARTVEST, TEPEZZA, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, VOWST, WAINUA, ZEPBOUND, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error